Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
Gülen Hatemi(Center for Rheumatology), Yusuf Yazıcı(Io Therapeutics (United States)), Cengiz Korkmaz(Eskişehir Osmangazi University), Melike Melikoğlu(Istanbul University-Cerrahpaşa), Cem Mat(Access to Wholistic and Productive Living Institute), Recep Tunç(Selçuk University), Ziqi Liu(Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital), Banu Öztürk(Selçuk University), Hasan Yazıcı(Istanbul University), Peter A. Merkel(University of Pennsylvania), Kenneth Calamia(Jacksonville College), Lilia Pineda(Hofstra University), Randall M. Stevens
Cited by 241
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
2018 update of the EULAR recommendations for the management of Behçet's syndrome
|Annals of the Rheumatic Diseases|2018|771
The Long-Term Mortality and Morbidity of Behçet Syndrome
|Medicine|2003|757
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721
A Controlled Trial of Azathioprine in Behçet's Syndrome
|New England Journal of Medicine|1990|646